null

null

null

null

null

null

null

null

null

Near-zero debt; cash-funded clinical-stage biotech with ~AUD 50M cash runway; 20% rate rise has negligible P&L impact

Minimal direct sensitivity; no material floating-rate debt; higher rates increase opportunity cost of cash holdings and raise future equity dilution cost

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) European GMP biologics manufacturers (efti supply); 2) US/EU clinical-site reagent and CRO concentration risk

Pre-revenue clinical stage; no meaningful international revenue streams; currency devaluation exposure limited to AUD/USD/EUR operating cost translation

Operations span Australia, US, EU; AUD functional currency; EUR and USD cash holdings create modest FX translation exposure on grants and trial costs

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single-source biologics CMO for eftilagimod alpha (efti) represents non-substitutable critical input; switching would require 12-24 month revalidation

Clinical-stage pharma; no cloud-infrastructure revenue model; AWS/GCP termination would disrupt data management but not core IP or trial operations

Secondary operational disruption: electronic data capture and trial management platforms (e.g., Medidata) are greater operational dependencies than cloud hyperscalers

Low API coupling risk; uses standard CRO/EDC platforms; core value resides in proprietary LAG-3 biological IP, not software integrations

Not applicable; revenue model is pharma licensing/milestone-based; no token, investment contract, or profit-sharing scheme involved

Very High

Moderate GDPR exposure via EU clinical trial patient data; CCPA limited; compliance managed through CRO agreements and standard ICH-GCP data protocols

Low antitrust risk; small-cap clinical-stage company with no market dominance; partnership agreements with large pharma (GSK, Merck) are standard co-development deals

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based; occasional research grants; no recurring subscription revenue; entirely dependent on partnership milestones and future royalties

Pharma licensing, milestone payments, and future royalties from LAG-3 immunotherapy programs; near-term revenue from collaboration agreements

Milestone and royalty pricing set by negotiation with big-pharma partners; no direct product pricing power until commercialization; vulnerable to partner renegotiation

Low current pricing power as pre-commercial licensor; potential high power post-approval if efti demonstrates differentiated OS benefit in breast cancer/NSCLC

Target gross margin 80-90%+ post-commercialization (biotech royalty/licensing norm); currently negative as R&D spend dominates

No free-rider leakage applicable; clinical partnerships are contractually bound; risk is partner termination of co-development agreements (e.g., Merck KEYNOTE-884 halt)

Headcount-sublinear growth model; ~30-40 FTE core team outsources trials to CROs; doubling pipeline does not require doubling headcount

Marginal cost of growth is clinical trial spend (CRO/site costs), not headcount; largely variable and outsourced, preserving fixed-cost leverage

Not applicable; no franchise network

At 10x scale (multiple approved indications), CAC model shifts to pharma sales force partnerships; unit economics depend on royalty rates (typically 10-20% net sales)

No traditional network effect; scientific data network effect exists as each trial strengthens LAG-3 platform evidence, attracting further partnership interest

AI displacement risk low for core immunotherapy R&D; AI may accelerate trial design and biomarker analysis but cannot replace GMP manufacturing or clinical execution

Moderate recession resistance; clinical funding depends on equity markets and partner budgets; oncology drugs maintain priority but discretionary trial expansions may be deferred

Large pharmaceutical and biotech companies (GSK, Merck KGaA) as licensing/co-development partners

Government and non-profit research grant bodies (NHMRC, EU Horizon) providing non-dilutive funding

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated almost entirely to future-state R&D (clinical trials, IP); no legacy infrastructure drag; ~85-90% of spend is clinical and regulatory pipeline investment

0001506184

IMMP